News

Published on 20 Jun 2024 on GuruFocus.com · via Yahoo Finance

Insider Sale: Chief Medical Officer Jonathan Slonin Sells Shares of Pacira...


Article preview image

Jonathan Slonin, Chief Medical Officer of Pacira BioSciences Inc (NASDAQ:PCRX), executed a sale of 5,012 shares of the company on June 11, 2024, as reported in a recent SEC Filing. Following this transaction, the insider now owns 98,869.475 shares of the company.

Warning! GuruFocus has detected 3 Warning Sign with PCRX.

Pacira BioSciences Inc (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company primarily engages in the development of non-opioid products for the management of post-surgical pain.

NASDAQ.PCRX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?

Other Stocks to Consider Here are some stocks worth considering from the healthcare space, as our...

Zacks · via Yahoo Finance 17 Feb 2025

HALO Gears Up to Report Q4 Earnings: Here's What You Should Know

Halozyme's fourth-quarter earnings are likely to have gained from higher royalty payments and...

Zacks · via Yahoo Finance 13 Feb 2025

New Strong Buy Stocks for February 11th

Dana Incorporated Price and Consensus Dana Incorporated price-consensus-chart | Dana Incorporated...

Zacks · via Yahoo Finance 11 Feb 2025

Best Value Stocks to Buy for February 11th

The company possesses a Value Score of A. OMV AG PE Ratio (TTM) OMV AG pe-ratio-ttm | OMV AG Quot...

Zacks · via Yahoo Finance 11 Feb 2025

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with t...

Zacks · via Yahoo Finance 17 Jan 2025

Small Business - Cordele Dispatch | Cordele Dispatch

NEW ORLEANS, Jan. 15, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information servic...

Cordele Dispatch 16 Jan 2025

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

Pacira stock gains 11% on better-than-expected preliminary Q4 sales figures. It also shares a...

Zacks · via Yahoo Finance 13 Jan 2025

Pacira BioSciences Inc (PCRX) Q3 2024: Everything You Need To Know Ahead Of...

Pacira BioSciences Inc (NASDAQ:PCRX) is set to release its Q3 2024 earnings on Nov 6, 2024. The...

GuruFocus.com · via Yahoo Finance 5 Nov 2024

Insider Sale: Chief Medical Officer Jonathan Slonin Sells Shares of Pacira...

Jonathan Slonin, Chief Medical Officer of Pacira BioSciences Inc (NASDAQ:PCRX), executed a sale o...

GuruFocus.com · via Yahoo Finance 20 Jun 2024

Earnings Miss: Pacira BioSciences, Inc. Missed EPS By 17% And Analysts Are Revising Their Forecasts

Investors in Pacira BioSciences, Inc. (NASDAQ:PCRX) had a good week, as its shares rose 9.3% to c...

Simply Wall St. via Yahoo Finance 10 May 2024